Medtronic has reported positive results from a clinical trial designed to evaluate the use of its cardiac resynchronisation therapy-defibrillators (CRT-Ds) on mildly symptomatic heart failure patients.
The double-blinded, randomised and controlled trial enrolled 1,798 mild-to-moderate heart failure patients in Canada, Europe and Australia to compare the CRT-D to Medtronic’s implantable cardioverter defibrillator (ICD).
Its primary endpoint was a composite of total mortality and heart failure hospitalisation.
The results showed revealed a 29% reduction in mortality rate among patients treated with CRT-Ds compared to those treated with the ICDs plus medical therapy.
In addition, there was a 27% reduction in combined mortality and heart failure hospitalisations in patients treated with CRT-Ds compared to those treated with ICDs.
Pat Mackin, senior vice-president at Medtronic, said that the research is the first to show the significant lifesaving value of CRT-Ds for mildly symptomatic heart failure patients.